You are here

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis

sandy craine's picture
Submitted by sandy craine on Fri, 11/11/2011 - 1:22pm

Variant Philadelphia (Ph) chromosome translocations have been reported in 5%-10% of patients with newly diagnosed chronic myeloid leukemia (CML). Variant translocations may involve one or more chromosomes in addition to 9 and 22, and can be generated by 2 different mechanisms, 1-step and 2-step rearrangements, as revealed by fluorescence in situ hybridization. The prognostic significance of the occurrence of variant translocations has been discussed in previous studies. The European LeukemiaNet recommendations do not provide a “warning” for patients with variant translocations, but there is limited information about their outcome after therapy with tyrosine kinase inhibitors. To identify the role of variant translocations in early chronic phase (CP) CML patients treated with imatinib mesylate, we performed an analysis in a large series of 559 patients enrolled in 3 prospective imatinib trials of the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on CML. Variant translocations occurred in 30 patients (5%). Our data show that the presence of variant translocations has no impact on the cytogenetic and molecular response or on outcome, regardless of the involvement of different mechanisms, the number of involved chromosomes, or the presence of deletions. Therefore, we suggest that patients with variant translocations do not constitute a “warning” category in the imatinib era.

Variant Philadelphia (Ph) chromosome translocations have been reported in 5%-10% of patients with newly diagnosed chronic myeloid leukemia (CML). Variant translocations may involve one or more chromosomes in addition to 9 and 22, and can be generated by 2 different mechanisms, 1-step and 2-step rearrangements, as revealed by fluorescence in situ hybridization. The prognostic significance of the occurrence of variant translocations has been discussed in previous studies. The European LeukemiaNet recommendations do not provide a “warning” for patients with variant translocations, but there is limited information about their outcome after therapy with tyrosine kinase inhibitors. To identify the role of variant translocations in early chronic phase (CP) CML patients treated with imatinib mesylate, we performed an analysis in a large series of 559 patients enrolled in 3 prospective imatinib trials of the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on CML. Variant translocations occurred in 30 patients (5%). Our data show that the presence of variant translocations has no impact on the cytogenetic and molecular response or on outcome, regardless of the involvement of different mechanisms, the number of involved chromosomes, or the presence of deletions. Therefore, we suggest that patients with variant translocations do not constitute a “warning” category in the imatinib era.

STIM Study Examines Sustainability of Complete Molecular Response After Stopping Imatinib in CML

sandy craine's picture
Submitted by sandy craine on Fri, 11/11/2011 - 1:14pm

 

STIM Study Examines Sustainability of Complete Molecular Response After Stopping Imatinib in CML

Elsevier Global Medical News. 2010 Jan 13, P Wendling

 

STIM Study Examines Sustainability of Complete Molecular Response After Stopping Imatinib in CML

Elsevier Global Medical News. 2010 Jan 13, P Wendling

Nilotinib vs imatinib in ph+CML: 24-month data from phase 3 ENESTnd trial

sandy craine's picture
Submitted by sandy craine on Thu, 03/11/2011 - 11:23am

 

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

 

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

SCT- CMV Virus vs Leukaemia Effect?

sandy craine's picture
Submitted by sandy craine on Mon, 10/10/2011 - 1:55pm

 

 

Ariad's TKI: ponatinib- PACE, a phase 11 clinical trial

sandy craine's picture
Submitted by sandy craine on Wed, 24/08/2011 - 1:49pm

 

A pivotal Phase 2 clinical trial of ARIAD’s investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), is ongoing in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).

 

A pivotal Phase 2 clinical trial of ARIAD’s investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), is ongoing in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).

ecancerTV interviews Hagop Kantarjian of MDACC.

sandy craine's picture
Submitted by sandy craine on Sat, 06/08/2011 - 3:09pm

This is a really interesting interview with Hagop Kantarjian of MDACC, Houston where he talks about the current therapies for CML. He has an interesting view on 2nd generation TKI in front line treatment and how that can be managed in the future given the increase in prevalence (patients living with cml) which will impact on the healthcare costs. He also has good things to say about patients with T315i mutation treated with ponatinib. 

This is a really interesting interview with Hagop Kantarjian of MDACC, Houston where he talks about the current therapies for CML. He has an interesting view on 2nd generation TKI in front line treatment and how that can be managed in the future given the increase in prevalence (patients living with cml) which will impact on the healthcare costs. He also has good things to say about patients with T315i mutation treated with ponatinib. 

UK National CML Patinet/Carer Seminar- Cardiff 12th November 2011

sandy craine's picture
Submitted by sandy craine on Tue, 02/08/2011 - 10:01pm

Dr Andrew Goringe,  Consultant Haematologist in Cardiff  recommends that you 'save the date' for this years annual CML patient/carer day on 12 November 2011 in Cardiff.

Dr Andrew Goringe,  Consultant Haematologist in Cardiff  recommends that you 'save the date' for this years annual CML patient/carer day on 12 November 2011 in Cardiff.

Carcinogenicity of radiofrequency electromagnetic fields

sandy craine's picture
Submitted by sandy craine on Sat, 25/06/2011 - 7:47pm
In May, 2011, 30 scientists from 14 countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to assess the carcinogenicity of radiofrequency electromagnetic fields (RF-EMF).

In May, 2011, 30 scientists from 14 countries met at the International
Agency for Research on Cancer (IARC) in Lyon, France, to assess the carcinogenicity of radiofrequency electromagnetic fields (RF-EMF).

Pages